The Pharmacy Times® Digestive Health Resource Center is a comprehensive resource for clinical news and expert insights on issues related to health of the digestive system, including Crohn disease, inflammatory bowel disease, irritable bowel syndrome, and ulcerative colitis.
March 28th 2023
The results of the INSPIRE trial demonstrated that 20.3% of individuals receiving risankizumab (Skyrizi) achieved clinical remission compared to 6.2% of individuals who received the placebo.
Preventing and Managing Controlled Substance Diversion Across Health Care Settings
2.0 Credits / Law
View More
Preventing and Managing Controlled Substance Diversion Across Health Care Settings
2.0 Credits / Law
View More
Integrating Sphingosine-1-Phosphate (S1P) Receptor Modulators in the Management of Ulcerative Colitis: The Pharmacist’s Role on the Interdisciplinary Team
1.5 Credits / Gastroenterology, Immunology
View More
Preventing and Managing Controlled Substance Diversion Across Health Care Settings
2.0 Credits / Law
View More
Integrating Sphingosine-1-Phosphate (S1P) Receptor Modulators in the Management of Ulcerative Colitis: The Pharmacist’s Role on the Interdisciplinary Team
1.5 Credits / Gastroenterology, Immunology
View More
Oral Chemotherapy Parity Legislation: Opportunities for Cancer Care Equity
1.0 Credit / Law, Oncology
View More
Exploring the Promising Role of Sphingosine-1-Phosphate Receptor Modulators for the Treatment of Ulcerative Colitis: A Review for Specialty Pharmacists
1.5 Credits / Gastroenterology, Immunology
View More
Oral Chemotherapy Parity Legislation: Opportunities for Cancer Care Equity
1.0 Credit / Law, Oncology
View More
Exploring the Promising Role of Sphingosine-1-Phosphate Receptor Modulators for the Treatment of Ulcerative Colitis: A Review for Specialty Pharmacists
1.5 Credits / Gastroenterology, Immunology
View More
Exploring the Promising Role of Sphingosine-1-Phosphate Receptor Modulators for the Treatment of Ulcerative Colitis: A Review for Specialty Pharmacists
1.5 Credits / Gastroenterology, Immunology
View More
Exploring the Promising Role of Sphingosine-1-Phosphate Receptor Modulators for the Treatment of Ulcerative Colitis: A Review for Specialty Pharmacists
1.5 Credits / Gastroenterology, Immunology
View More
Dupixent Shows Positive Results for Children Under 12 with Eosinophilic Esophagitis in Phase 3 Trial
July 20th 2022Dupilumab (Dupixent) is the first medicine to improve signs of eosinophilic esophagitis and support weight gain in children ages 1 to 11, for whom there are no currently approved treatments.
Read More
Clinical Overview: Cyletzo, a Biosimilar Version of Adalimumab
July 19th 2022Indications for adalimumab include ankylosing spondylitis, Crohn disease, chronic plaque psoriasis, juvenile idiopathic arthritis, moderate to severe rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis.
Read More